SCHEMBL16187091

SCHEMBL16187091

CN(CCN)Cc1c[nH]nc1C1CCC1

nearest known ligand 0.42

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ CARM1 Q86X55 19/20 0.42
▸ PRMT1 Q99873 17/20 0.42
▸ PRMT6 Q96LA8 4/20 0.37
▸ PRMT8 Q9NR22 4/20 0.37
▸ PRMT3 O60678 3/20 0.36
▸ BCHE P06276 1/20 0.32
▸ ACHE P22303 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16187094 0.97 CARM1 (0.45) CARM1PRMT1PRMT6PRMT8PRMT3
SCHEMBL16187088 0.96 CARM1 (0.47) CARM1PRMT1PRMT6PRMT8PRMT3
SCHEMBL16187080 0.94 CARM1 (0.41) CARM1PRMT1PRMT6PRMT8PRMT3
SCHEMBL16121733 0.89 CARM1 (0.39) CARM1PRMT1PRMT6PRMT8PRMT3
SCHEMBL17467642 0.87 PRMT1 (0.38) CARM1PRMT1PRMT6PRMT8PRMT3
SCHEMBL16122002 0.87 PRMT1 (0.50) CARM1PRMT1PRMT6PRMT8PRMT3
SCHEMBL19222437 0.86 CARM1 (0.34) CARM1PRMT1PRMT6PRMT8PRMT3
SCHEMBL16187120 0.84 HTR1D (0.39) CARM1PRMT1PRMT6PRMT8PRMT3
SCHEMBL22430339 0.84 CARM1 (0.37) CARM1PRMT1PRMT6PRMT8PRMT3
SCHEMBL16187107 0.83 HTR1D (0.39) CARM1PRMT1PRMT6PRMT8PRMT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11185531-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2021-11-30 — — US disclosed
US-20210078951-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. 2021-03-18 — — US disclosed
US-10800743-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2020-10-13 — — US disclosed
EP-2970132-B1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF EPIZYME INC (US) 2020-09-23 — — EP disclosed
US-20200289469-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. 2020-09-17 — — US disclosed
US-10632103-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2020-04-28 — — US disclosed
US-20190100496-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. 2019-04-04 — — US disclosed
US-20170291905-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-10-12 — — US disclosed
US-20170291905-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-10-12 — — US disclosed
US-20170267642-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-09-21 — — US disclosed
US-9598374-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2017-03-21 — — US disclosed
US-20160184267-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. 2016-06-30 — — US disclosed
US-20160184267-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. 2016-06-30 — — US disclosed
WO-2016044626-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-03-24 — — WO disclosed
US-20160024016-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-01-28 — — US disclosed
US-20160024016-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-01-28 — — US disclosed
US-9120757-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2015-09-01 — — US disclosed
US-9120757-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2015-09-01 — — US disclosed
US-20140315904-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-23 — — US disclosed
US-20140315904-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11185531-B2 Arginine methyltransferase inhibitors and uses thereof PRMT1, PRMT3, PRMT5 CARM1 11/4885PRMT1 1/4885PRMT6 4/4885
US-10800743-B2 Arginine methyltransferase inhibitors and uses thereof PRMT1, PRMT3, PRMT5 CARM1 11/4885PRMT1 1/4885PRMT6 4/4885
US-20210078951-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 CARM1 11/4885PRMT1 1/4885PRMT6 4/4885
US-20170267642-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 CARM1 11/4885PRMT1 1/4885PRMT6 4/4885
US-20200289469-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 CARM1 11/4885PRMT1 1/4885PRMT6 4/4885
US-10632103-B2 Arginine methyltransferase inhibitors and uses thereof PRMT1, PRMT3, PRMT5 CARM1 11/4885PRMT1 1/4885PRMT6 4/4885
US-20190100496-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 CARM1 11/4885PRMT1 1/4885PRMT6 4/4885
US-20140315904-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 CARM1 11/4885PRMT1 1/4885PRMT6 4/4885
US-20160184267-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 CARM1 11/4885PRMT1 1/4885PRMT6 4/4885
US-20160024016-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 CARM1 11/4885PRMT1 1/4885PRMT6 4/4885
US-20170291905-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT6 CARM1 12/4885PRMT1 1/4885PRMT6 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback